{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["apalutamide","abiraterone"],["ipilimumab","apalutamide","abiraterone"]],"indication":"metastatic castration-resistant prostate cancer","name":"NCT02703623","nct_id":"NCT02703623","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02703623. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.","label":"Arm 2A (abiraterone acetate, prednisone, apalutamide)","type":"EXPERIMENTAL"},{"description":"Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.","label":"Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)","type":"EXPERIMENTAL"},{"description":"Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.","label":"Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2028-03-31","type":"ESTIMATED"},"conditions":["Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","PSA Progression","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":{"count":196,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Abiraterone Acetate","otherNames":["CB7630","Zytiga"],"type":"DRUG"},{"name":"Apalutamide","otherNames":["ARN 509","ARN-509","ARN509","JNJ 56021927","JNJ-56021927"],"type":"DRUG"},{"name":"Cabazitaxel","otherNames":["Jevtana","RPR-116258A","Taxoid XRP6258","XRP-6258"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS-734016","MDX-010","MDX-CTLA4","Yervoy"],"type":"BIOLOGICAL"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Prednisone","otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisonum","Prednitone","Promifen","Servisone","SK-Prednisone"],"type":"DRUG"}],"last_update":"2026-09-14","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"Up to 4 years"},{"measure":"Incidence of adverse events as measured by the method of Thall et al","timeFrame":"Up to 4 years"},{"measure":"Androgen receptor (AR) response marker signature","timeFrame":"At baseline"},{"measure":"Allocation serum marker decline","timeFrame":"At 8 weeks"}],"references":[],"start_date":{"date":"2016-05-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT02703623"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02703623"}